Lupus & antiphospholipid syndrome
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA
Study context
- Population
- Adults with incident SLE in the USA, MarketScan claims 2011–2019; 24-month pre-index and ≥24-month post-index periodreceived SLE treatment
- Participants
- 2,476 adults
- Outcome
- Treatment patterns, medication adherence, concomitant corticosteroid use, factors influencing sequence of therapies (SOTs), healthcare resource utilisation (HCRU) and associated costs
Methodological detailsclaims database (Merative MarketScan Commercial and Medicare Supplemental), descriptive statistics, multivariable-adjusted logistic regression, Mean (SD) age 46.9 (14.1) years; mean (SD) follow-up 47.8 (15.7) months
- Claims database (Merative MarketScan Commercial and Medicare Supplemental)
- Descriptive statistics
- Multivariable-adjusted logistic regression
- Mean (SD) age 46.9 (14.1) years; mean (SD) follow-up 47.8 (15.7) months
Main finding
As reported in the abstract
Treatment patterns across SOTs
- Corticosteroid use (≥1 corticosteroid) in all sequence of therapies (SOTs), % patients
- 50%-60%
- Corticosteroid average dose
- 16.8-19.3 mg/day
- Antimalarials in SOT 1
- 85.7%
- Immunosuppressants in SOT 2
- 85.4%
- Immunosuppressants in SOT 3
- 77.5%
- Transition SOT 1-2
- 38.4%
- Transition SOT 2-3
- 16.9%
Observational data: associations, not effects.
Further findings
SLE-related HCRU costs (increased with SOT progression)
Original publication
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA. Lupus Sci Med. Published 23 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →